Alpha Modus Settles Lawsuit Against Walgreens Over In-Store Technology Patents
Alpha Modus (NASDAQ: AMOD), a leader in AI-powered retail technology, has announced the settlement of its patent infringement lawsuit against Walgreens. The lawsuit, filed in the Eastern District of Texas, involved claims related to Alpha Modus's U.S. Patent Nos. 10,977,672 and 11,042,890.
While the settlement terms remain confidential, the lawsuit will be dismissed with prejudice. CEO William Alessi emphasized the company's commitment to protecting intellectual property while maintaining positive industry relationships. The company continues to pursue its IP monetization strategy through licensing and litigation opportunities.
Alpha Modus (NASDAQ: AMOD), azienda leader nelle soluzioni retail potenziate dall'IA, ha annunciato la risoluzione della causa per violazione di brevetto intentata contro Walgreens. Il procedimento, avviato presso l'Eastern District of Texas, riguardava i brevetti statunitensi n. 10,977,672 e 11,042,890 di Alpha Modus.
Le condizioni dell'accordo sono riservate, ma la causa sarà archiviata con giudizio definitivo (dismissed with prejudice). Il CEO William Alessi ha sottolineato l'impegno dell'azienda nella tutela della proprietà intellettuale mantenendo rapporti costruttivi nel settore. L'azienda prosegue la sua strategia di monetizzazione della PI tramite licenze e azioni legali mirate.
Alpha Modus (NASDAQ: AMOD), líder en tecnología minorista impulsada por IA, ha anunciado la resolución de su demanda por infracción de patentes contra Walgreens. La demanda, presentada en el Distrito Este de Texas, se refería a las patentes estadounidenses nº 10.977.672 y 11.042.890 de Alpha Modus.
Los términos del acuerdo son confidenciales, pero la demanda se desestimará con perjuicio (dismissed with prejudice). El CEO William Alessi resaltó el compromiso de la compañía con la protección de la propiedad intelectual, al tiempo que mantiene relaciones positivas en la industria. La empresa continúa con su estrategia de monetización de PI mediante licencias y acciones legales.
Alpha Modus (NASDAQ: AMOD), AI 기반 소매 기술 선도기업이 Walgreens를 상대로 한 특허 침해 소송이 합의로 종결되었다고 발표했습니다. 이 소송은 텍사스 동부 지방법원에 제기된 것으로, Alpha Modus의 미국 특허 번호 10,977,672 및 11,042,890과 관련된 청구를 포함하고 있었습니다.
합의 조건은 비공개이며, 소송은 기각 처리(dismissed with prejudice)될 예정입니다. CEO William Alessi는 지적재산권 보호에 대한 회사의 의지를 강조하면서도 업계와의 긍정적인 관계 유지를 언급했습니다. 회사는 라이선스 및 소송 기회를 통한 IP 수익화 전략을 계속 추진하고 있습니다.
Alpha Modus (NASDAQ: AMOD), leader des technologies retail alimentées par l'IA, a annoncé le règlement de son procès pour contrefaçon de brevet contre Walgreens. La plainte, déposée dans le district Est du Texas, portait sur les brevets américains n° 10,977,672 et 11,042,890 d'Alpha Modus.
Les modalités de l'accord restent confidentielles, mais l'affaire sera classée avec préjudice (dismissed with prejudice). Le PDG William Alessi a souligné l'engagement de la société à protéger sa propriété intellectuelle tout en maintenant des relations positives dans le secteur. La société poursuit sa stratégie de monétisation de la PI via des licences et des actions en justice.
Alpha Modus (NASDAQ: AMOD), ein führendes Unternehmen für KI-gestützte Einzelhandelslösungen, hat die Beilegung seiner Patentverletzungsklage gegen Walgreens bekanntgegeben. Die Klage, eingereicht beim Eastern District of Texas, betraf die US-Patente Nr. 10.977.672 und 11.042.890 von Alpha Modus.
Die Bedingungen der Einigung sind vertraulich, die Klage wird jedoch mit Präjudiz abgewiesen (dismissed with prejudice). CEO William Alessi betonte das Bekenntnis des Unternehmens zum Schutz des geistigen Eigentums und zugleich zur Pflege positiver Branchenbeziehungen. Das Unternehmen verfolgt weiterhin seine Strategie zur Monetarisierung von IP durch Lizenzierung und gerichtliche Schritte.
- Successful resolution of patent infringement lawsuit against major retailer Walgreens
- Settlement demonstrates effectiveness of company's IP monetization strategy
- Company maintains ability to pursue additional licensing and litigation opportunities
- Confidential settlement terms prevent assessment of financial impact
- Ongoing litigation strategy may involve continued legal expenses
CORNELIUS, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings Inc. (NASDAQ: AMOD), a leader in AI-powered retail technology, today announced that it has reached a settlement in its patent infringement lawsuit against Walgreen Co. (“Walgreens”).
The case, Alpha Modus, Corp. v. Walgreen Co., was filed in the United States District Court for the Eastern District of Texas (Case No. 2:25-cv-00120) and involved claims related to Alpha Modus’s U.S. Patent Nos. 10,977,672 and 11,042,890.
The terms of the settlement are confidential. The lawsuit will be dismissed with prejudice.
“We appreciate the opportunity to amicably resolve this matter in a timely and effective manner,” said William Alessi, Chief Executive Officer of Alpha Modus. “This outcome reflects our continued commitment to safeguarding the value of our intellectual property while promoting constructive relationships across the retail and technology sectors.”
Alpha Modus has now resolved multiple enforcement actions as part of its broader IP monetization strategy and continues to pursue licensing and litigation opportunities involving its patented technologies.
For more information, visit: www.alphamodus.com
About Alpha Modus Holdings Inc.
Alpha Modus Holdings Inc. (NASDAQ: AMOD) is redefining the retail experience through its patented AI technologies, intelligent kiosks, and targeted consumer engagement tools. By integrating innovation with infrastructure, Alpha Modus is unlocking new monetization pathways for retailers and fintech providers alike.
For more information and to access Alpha Modus’ press room, visit: https://alphamodus.com/press-room/
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Alpha Modus’s actual results may differ from their expectations, estimates, and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Alpha Modus’s expectations with respect to future performance.
Alpha Modus cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Alpha Modus does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
Contact Information
Investor Relations
Alpha Modus Holdings, Inc.
Email: ir@alphamodus.com
Website: www.alphamodus.com
Follow us on LinkedIn | Follow us on X
FAQ
What was the outcome of Alpha Modus's (AMOD) patent lawsuit against Walgreens?
Which patents were involved in Alpha Modus's lawsuit against Walgreens?
What is Alpha Modus's (AMOD) strategy for patent monetization?
Who is the CEO of Alpha Modus (AMOD)?
Where was Alpha Modus's patent infringement lawsuit against Walgreens filed?
